^
    Back
    Association details:
    Biomarker:EGFR L858R + ROS1 fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Endostar (recombinant human endostatin) (VEGF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Thorac Cancer
    Title:

    Chemotherapy combined with Endostar as salvage treatment for EGFR-tyrosine kinase inhibitor primary resistance in an advanced non-small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: A case report

    Published date:
    02/18/2019
    Excerpt:
    In our case, a non-small cell lung cancer patient developed intrinsic EGFR-TKI resistance and was then confirmed to simultaneously harbor an L858R mutation and ROS1 rearrangement. Salvage chemotherapy plus Endostar showed enduring therapeutic effects, achieving a disease-free survival period of 24 months and overall survival of 30 months.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1111/1759-7714.13003